Business Wire

WORLD-ANTI-SMOKING-PLCY

3.4.2024 07:01:29 CEST | Business Wire | Press release

Share
Worldwide Anti-Smoking Policies Charted in Comprehensive Index

We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index (https://antismoking.global/). The index assesses around 5.5 billion people, nearly 70 percent of the world's population. It offers an analysis of the public policies to eradicate smoking in 69 countries across four regions. The Index delves into the intricacies of alternative nicotine products, scrutinizing aspects such as regulatory frameworks, prohibitions, taxation, and governmental measures for switching from smoking.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402477735/en/

The top 20 countries in the global anti-smoking index, led by the United Kingdom, Sweden, and Slovakia in the podium positions, collectively impact almost 1 billion people worldwide. European nations dominate the list, with 15 out of the 20 spots occupied by countries from this region. However, non-European nations like the United States, Lebanon, New Zealand, Canada, and Saudi Arabia also make significant strides in terms of regulations.

The index emphasizes the urgent need for global advancements in anti-smoking policies. Finding a balance between traditional measures and innovative approaches, including alternative nicotine products, is key to success. The Index calls for a holistic approach encompassing alternative products to address the gaps in regulation.

Global policies differ radically in receptiveness, with vaping facing sales bans despite growing evidence on its harm reduction. Thus, seventeen countries have prohibited vaping. Tobacco Heated Products (THP) policies show similar regional bifurcation patterns. Thirteen countries prohibit THP, mostly in South America and Asia. Snus faces widespread prohibitions in the European Union, except in Sweden. China with bans on THP and nicotine pouches and heavy restriction of vaping and snus scored 51st place. India scored last globally for completely prohibiting all nicotine alternatives. In addition to forgoing harm reduction benefits, the blanket ban fuels illicit trade.

In the Americas, Canada and the United States are open to vaping and other alternatives, while many Latin American countries ban them. New Zealand leads in vaping in the Asia Pacific, while Australia, India, Japan, Thailand, and Vietnam have banned it. Japan, however, is the frontrunner for THP and snus.

In the MENA region, only Lebanon and Saudi Arabia have progressive harm reduction stances, while other countries prohibit alternatives. Nicotine pouches have avoided significant regulatory scrutiny, but their potential depends on recognition for health merits outside of the EU and US.

“With over 8 million lives lost annually to smoking-related diseases, the need for effective anti-smoking measures is more urgent than ever. Nations like Sweden and New Zealand are leading the way by embracing innovative nicotine products in the fight against smoking. Their public policies allowing alternatives have yielded remarkable results, with smoking rates around 5 percent - nearly smoke-free. This success highlights the vital role innovation must play in consigning smoking to history. Policymakers worldwide must follow the example set by these countries, fully harnessing safer products to uproot smoking's toll on global health,” stated Federico N. Fernandez, the CEO of We Are Innovation.

ABOUT WE ARE INNOVATION

We Are Innovation is a dynamic network of individuals and institutions who fervently believe in the power of innovation to drive progress and solve the world’s most pressing problems. With a global presence encompassing over 40 think tanks, foundations, and NGOs, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are spearheading transformative change on a global scale. To learn more visit us at https://weareinnovation.global/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402477735/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye